Novartis AG (NVS)

82.70
0.25 0.30
NYSE : Health Technology
Prev Close 82.45
Open 82.99
Day Low/High 82.70 / 83.32
52 Wk Low/High 72.30 / 96.31
Volume 1.56M
Avg Volume 2.48M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 209.88B
EPS 5.50
P/E Ratio 15.33
Div & Yield 1.84 (2.26%)
A Burst of Earnings Keeps Premarket Trade Busy, Stock Futures Rise

A Burst of Earnings Keeps Premarket Trade Busy, Stock Futures Rise

U.S. stock futures are higher on Tuesday, Oct. 24, looking to partially recover from losses seen a day earlier that swept benchmark indexes from record levels.

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

U.S. stock futures are rising on Tuesday, after Wall Street's record-breaking streak came to an end during the previous trading session.

How to Manage GE Risk and the Netflix-Disney Fight: Market Recon

How to Manage GE Risk and the Netflix-Disney Fight: Market Recon

Entering GE too early has its costs, but there are ways to mitigate them.

Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

European markets opened flat as investors await the European Central Bank meeting

Novartis Tops Estimates Boosted by New Drugs

Novartis Tops Estimates Boosted by New Drugs

The company is also undertaking a strategic review of its Alcon eye care business and said Tuesday that it indicates that creating a stand-alone company via a capital markets exit could create additional shareholder value.

Gilead Stock Climbs as FDA Approves Lymphoma Cancer Therapy Drug Yescarta

Gilead Stock Climbs as FDA Approves Lymphoma Cancer Therapy Drug Yescarta

The drug is anticipated to rake in $1.7 billion in worldwide sales in the next five years with a U.S. list price of $373,000.

European Stocks Euphoria Is Running High ... Maybe Too High

European Stocks Euphoria Is Running High ... Maybe Too High

European stock markets are priced almost to perfection ahead of an earnings deluge.

FDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder

FDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder

Spark Therapeutics gains gene therapy advisory OK for treatment restoring some sight for patients facing eventual blindness.

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Stocks look past the worst mass shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks look past the worst gun shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks begin the new month and quarter with gains on Monday, Oct. 2, as manufacturing conditions hold in expansion territory for another month.

Novartis CEO Joe Jimenez to Step Down in 2018

Novartis CEO Joe Jimenez to Step Down in 2018

Novartis CEO Joe Jimenez will step down next year to make room for chief medical officer Vas Narasimhan.

FDA Greenlights Novartis' Gene Therapy for Leukemia

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' Kymriah is the first gene therapy approved by the FDA.

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis' CAR-T Gene Therapy Receives FDA Approval

The treatment is the first of its kind to be authorized in the U.S.

StoneMor Shares Have Fallen Like a Stone

But even at this low level, the stock is no bargain.

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Jim Cramer is bullish on Novartis AG, Sirius XM Radio, Coupa Software and Juno Therapeutics.

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Regrets? One Was Slow Top-Line Growth, Says Outgoing Mondelez CEO

Regrets? One Was Slow Top-Line Growth, Says Outgoing Mondelez CEO

Dirk Van de Put of McCain Foods is the snack company's new CEO, starting in November.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are slightly higher on Tuesday, following the collapse of healthcare overhaul in the U.S.

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European stocks are firmly on the back foot.

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis sees stronger full-year Alcon sales

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

The second-quarter earnings season picks up speed.

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

TheStreet Quant Rating: B (Buy)